Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01371630

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:47.325664+00:00

Published At

2025-12-18T00:00:00+00:00

Record Updated At

2025-12-18

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Burkitt-Like Lymphoma With 11q Aberration", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Burkitt Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Burkitt Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2025-12-18"

protocolSection.identificationModule.nctId

"NCT01371630"

protocolSection.identificationModule.officialTitle

"Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (protocolSection.conditionsModule.conditions)
• B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (protocolSection.conditionsModule.conditions)
• Burkitt-Like Lymphoma With 11q Aberration (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Recurrent B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Burkitt Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.